Carregant...

Disease modifying potential of glatiramer acetate in Huntington's disease

BACKGROUND: Deficiencies in brain-derived-neurotrophic-factor have been implicated in the pathogenesis of Huntington's disease (HD). OBJECTIVE: Glatiramer acetate, an FDA- approved drug used for the treatment of multiple sclerosis, has been shown to increase brain-derived-neurotrophic-factor le...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Huntingtons Dis
Autors principals: Corey-Bloom, Jody, Jia, Haiqun, Aikin, Alaina M., Thomas, Elizabeth A.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4480978/
https://ncbi.nlm.nih.gov/pubmed/25300334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JHD-140110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!